SECTRAL (acebutolol hydrochloride) by ANI Pharmaceuticals is clinical pharmacology acebutolol is a cardioselective, β-adrenoreceptor blocking agent, which possesses mild intrinsic sympathomimetic activity (isa) in its therapeutically effective dose range. Approved for hypertension in adults, the management of ventricular premature beats, hypertension and 1 more indications. First approved in 1984.
Drug data last refreshed 16h ago · AI intelligence enriched 2w ago
SECTRAL (acebutolol hydrochloride) is a cardioselective beta-1 adrenergic receptor blocker with mild intrinsic sympathomimetic activity (ISA), approved in 1984 for hypertension and ventricular premature beats. It reduces heart rate, blood pressure, and cardiac workload while preserving some sympathomimetic effects that minimize effects on bronchi and peripheral vascular resistance. The drug's cardioselectivity and ISA profile make it a differentiated option in the beta-blocker class, particularly for patients with asthma or COPD comorbidities.
Product approaching loss of exclusivity with declining market footprint; brand teams typically consolidate to small maintenance groups focusing on generic transition and specialty positioning.
CLINICAL PHARMACOLOGY Acebutolol is a cardioselective, β-adrenoreceptor blocking agent, which possesses mild intrinsic sympathomimetic activity (ISA) in its therapeutically effective dose range. Pharmacodynamics β 1 -cardioselectivity has been demonstrated in experimental animal studies. In…
Worked on SECTRAL at ANI Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
SECTRAL offers minimal career growth opportunity as a mature, generic-threatened beta-blocker marketed by a smaller sponsor (ANI Pharmaceuticals). Roles are typically small, maintenance-focused teams managing market share decline and generic transition rather than driving innovation or expansion.